NCT01757392View on ClinicalTrials.gov

Candin Safety & Efficacy Study for the Treatment of Warts

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
WartsHuman Papilloma Virus
Interventions
BIOLOGICAL

Candida albicans Skin Test Antigen

0.3 ml injected intralesionally monthly. Number of injections: until wart lesion is resolved or up to 6 injections.

Trial Locations (1)

72916

Johnson Dermatology, Fort Smith

Sponsors
All Listed Sponsors
lead

Nielsen BioSciences, Inc.

INDUSTRY

NCT01757392 - Candin Safety & Efficacy Study for the Treatment of Warts | Biotech Hunter | Biotech Hunter